Tvardi Therapeutics (TVRD) Depreciation & Amortization (CF) (2013 - 2026)

Tvardi Therapeutics has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $24000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95000.0 (up 23.38% YoY) and the FY2025 annual result came in at $95000.0, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) held at $24000.0 in Q1 2026 per TVRD's latest filing, from $24000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $82000.0 in Q4 2023 and troughed at $5000.0 in Q2 2024.
• A 5-year average of $42411.8 and a median of $42000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) tumbled 91.67% in 2024, then jumped 360.0% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $61000.0 in 2022, then surged by 34.43% to $82000.0 in 2023, then tumbled by 70.73% to $24000.0 in 2024, then changed by 0.0% to $24000.0 in 2025, then changed by 0.0% to $24000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $24000.0, $24000.0, and $24000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.